US2010074946A1PendingUtilityA1
Process for preparing purified nucleic acid and the use thereof
Est. expiryFeb 6, 2016(expired)· nominal 20-yr term from priority
Inventors:Wolfgang Kuhne
C12N 15/101C12N 15/85A61K 48/0091A61P 11/00A61K 48/005A61P 11/16A61K 48/00C07H 1/08C12N 15/10
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether) n and with a content of below 1EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.
Claims
exact text as granted — not AI-modified1 . DNA preparation comprising a DNA, proteins in an amount of less than about 0.1% DNA and endotoxins in an amount of less than about 1 EU/mg DNA.
2 . The DNA preparation of claim 1 , comprising endotoxins of less than about 0.06 EU/mg DNA.
3 . The DNA preparation of claim 1 , comprising endotoxins of about 0.01 to 0.1 EU/mg DNA.
4 . The DNA preparation of claim 1 , wherein the DNA preparation is free of ethidium bromide, phenol, cesium chloride, octylphenolpoly(ethylene glycol ether) n detergents and MOPS buffer.
5 . The DNA preparation of claim 1 , wherein the DNA can be replicated in gram-negative bacteria.
6 . The DNA preparation of claim 15 , wherein the gram-negative bacteria is Escherichia coli.
7 . The DNA preparation of claim 1 , wherein the DNA is plasmid DNA.
8 . The DNA preparation of claim 7 , wherein the plasmid DNA is capable of replication.
9 . A pharmaceutical composition suitable for gene therapy comprising a therapeutically effective amount of the DNA preparation of claim 5 and a pharmaceutically acceptable carrier.
10 . The composition of claim 9 , wherein the DNA preparation contains endotoxins in an amount of less than about 0.06 EU/mg DNA.
11 . The composition of claim 9 , wherein the DNA preparation contains endotoxins in an amount of about 0.01 to 0.1 EU/mg DNA.
12 . The composition of claim 9 , wherein the DNA is a plasmid DNA.
13 . The composition of claim 12 , wherein the plasmid DNA is encapsulated in liposomes.
14 . A method for gene therapy of cystic fibrosis caused by the absence of a normal first gene or the presence of a defective second gene, comprising administering an effective amount of the DNA preparation of claim 18 to a patient in need thereof, wherein the plasmid DNA contains said normal first gene or a normal second gene corresponding to the defective second gene.
15 . A process for making the DNA preparation of claim 1 , comprising the following steps
(a) providing gram-negative bacteria containing said DNA; (b) lysing said bacteria to obtain a lysate, wherein the lysate is a DNA-containing fraction and thereafter (c) chromatographing said DNA-containing fraction on hydroxylapatite in order to obtain said DNA preparation.
16 . The method of claim 15 , further comprising replicating said DNA in gram-negative bacteria after step (a) and before step (b).
17 . The method of claim 16 , further comprising transfecting the gram-negative bacteria with a cloning vector containing said DNA before step (a).
18 . The method of claim 16 , further comprising eluting said hydroxylapatite in step (c) with a solution of phosphate, citrate, sulfate or divalent metal ions to obtain said DNA preparation.
19 . The method of claim 15 , further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
20 . The method of claim 16 , further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
21 . The method of claim 17 , further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
22 . The method of claim 18 , further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.Join the waitlist — get patent alerts
Track US2010074946A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.